A Single-Center In Vitro Study to Evaluate GSK1325756 Inhibition of CD11b Cell Surface Expression in Healthy Adults and Respiratory Syncytial Virus-Infected Children <2 Years (200591)
Latest Information Update: 22 Jun 2023
At a glance
- Drugs Danirixin (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors GSK
- 17 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2015 New trial record